Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Treatment-induced neuroendocrine prostate cancer and de novo neuroendocrine prostate cancer: Identification, prognosis and survival, genetic and epigenetic factors

24 Apr 2024

Abstract excerpt

Neuroendocrine prostate cancer (NEPC) shows an aggressive behavior compared to prostate cancer (PCa), also known as prostate adenocarcinoma. Scanty foci in PCa can harbor genetic alternation that can arise in a heterogeneity of prostate cancer. NEPC may arise de novo or develop following androgen deprivation therapy (ADT). NEPC that arise following ADT has the nomenclature “treatment-emerging/induced NEPC...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Lung Cancer Research Studies
Share to Prostate Cancer Treatment and Research
Share to Radiopharmaceutical Chemistry and Applications

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38808339
DOI: 10.12998/wjcc.v12.i13.2143

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Treatment-induced neuroendocrine prostate cancer and de novo neuroendocrine prostate cancer: Identification, prognosis and survival, genetic and epigenetic factorsPMID 38808339Read ↗

Role of MicroRNAs in Neuroendocrine Prostate CancerSemantic proximity Read ↗

[Neuroendocrine prostate cancer: Natural history, molecular features, therapeutic management and future directions].Semantic proximity Read ↗

Neuroendocrine Prostate Cancer: Subtypes, Biology, and Clinical OutcomesSemantic proximity Read ↗

Gene Expression Signature Predictive of Neuroendocrine Transformation in Prostate AdenocarcinomaSemantic proximity Read ↗

Targeting Key Players of Neuroendocrine Differentiation in Prostate Cancer.Semantic proximity Read ↗

Targeting Key Players of Neuroendocrine Differentiation in Prostate CancerSemantic proximity Read ↗

Treatment-related Neuroendocrine Prostate Carcinoma—Diagnostic and Molecular CorrelatesSemantic proximity Read ↗

Therapeutic Exploitation of Neuroendocrine Transdifferentiation Drivers in Prostate CancerSemantic proximity Read ↗

Molecular model for neuroendocrine prostate cancer progressionSemantic proximity Read ↗

Real-world experience in treatment outcome and genomic insights for metastatic prostate neuroendocrine carcinoma.Semantic proximity Read ↗

The central role of Sphingosine kinase 1 in the development of neuroendocrine prostate cancer (NEPC): A new targeted therapy of NEPCSemantic proximity Read ↗

Aggressive variants of prostate cancer: underlying mechanisms of neuroendocrine transdifferentiationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.